Clinical trials
Fatty Liver clinical trials
Below are recruiting fatty liver clinical trials, each written for real people, not researchers. We’re tracking 166 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05480696RecruitingPhase 2
Soluble fiber supplement for fatty liver in kids
This Phase 2 study tests whether a soluble fiber supplement can improve fatty liver disease in children who have obesity and confirmed NAFLD. It may help reduce liver fat and related liver enzyme elevations measured during clinic visits and MRI.
Hamilton, OntarioAges 8–17 - NCT06585982Recruiting
Synbiotics for MAFLD: gut health and liver fat study
This trial tests whether taking a synbiotic (a mix of helpful bacteria and fiber) can improve insulin levels and reduce inflammation in people with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). It may help by changing the balance of bacteria in your gut.
Semarang, SemarangAges 25–55 - NCT05618626Recruiting
Lifestyle program to prevent fatty liver and heart disease
This trial tests whether a structured lifestyle program—focused on healthy living and resistance exercise—can help prevent fatty liver disease and heart-related problems. It may be helpful if you have early or mild fatty liver changes or risk factors, even if you also have gallstones.
Molina, Maule RegionAges 45–60 - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT05165706Recruiting
Study of how obesity affects insulin resistance over time
This study follows adults over time to understand how weight and body chemistry relate to insulin resistance. It may help researchers learn why insulin resistance happens and what could prevent or improve it.
Stanford, CaliforniaAges 35–65 - NCT07493967Enrolling by invitation
Stomach balloon for fatty liver disease study
This study looks at how a stomach balloon affects symptoms and quality of life in people with obesity and fatty liver disease. It will track your health over time to see if the balloon helps.
Dallas, TexasAges 18 years+ - NCT07495332Recruiting
Liver imaging study using new biomarkers
This study tests whether a new type of MRI scan can better detect and measure liver disease, including fatty liver and scarring, compared to standard CT scans. If you have chronic liver disease, this study may help improve how we diagnose and track it.
Durham, North CarolinaAges 18 years+ - NCT06694935RecruitingPhase 1
Testing QX1206 in type 2 diabetes with fatty liver
This trial tests a new pill called QX1206 for people who have both Type 2 diabetes and fatty liver disease (NAFLD). The goal is to see if the medicine is safe and can help improve both conditions.
TorontoAges 18–64 - NCT03875625Recruiting
Tracking body fat and liver fat after weight-loss treatment
This study looks at how body fat and liver fat change after bariatric (weight-loss) surgery or a lifestyle program. You may join if you have overweight or obesity and can safely have MRI scans, so researchers can compare results between treatment approaches.
Hong Kong, ShatinAges 18–65 - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT07376486Recruiting
Early treatment for type 2 diabetes using a new duodenal procedure
This study tests a new procedure called pulsENDO, which is done in the first part of the small intestine (the duodenum) to help treat type 2 diabetes. It may be an option for people who were recently diagnosed and have good blood sugar control with little or no diabetes medication.
ShatinAges 18–60 - NCT07358546RecruitingPhase 1
Test of efimosfermin alfa in adults with liver problems
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Rialto, CaliforniaAges 18–70 - NCT06883578Recruiting
Effect of a low valine diet on body weight and metabolism
This trial studies if a diet low in valine, a building block of protein, can help people with excess weight lose weight and improve their metabolic health. It may offer an alternative approach for weight loss.
Shanghai, Shanghai MunicipalityAges 16–80 - NCT06890169Recruiting
One-stop telehealth program for weight and diabetes
This trial tests a telehealth program that helps people lose weight and manage type 2 diabetes and fatty liver disease at the same time. It's a one-stop remote clinic that combines medical advice, nutrition, and lifestyle support.
SingaporeAges 21–70 - NCT05984745RecruitingPhase 2
CoQ10 for fatty liver linked to metabolic issues
This study tests if CoQ10 (a natural supplement) can improve liver health in people with metabolic dysfunction-associated fatty liver disease (MAFLD). It may help if you have a fatty liver and related metabolic issues like high blood pressure or diabetes.
CairoAges 18–80 - NCT07246421Recruiting
Glucagon resistance in fatty liver and diabetes
This study looks at how people with fatty liver and type 2 diabetes respond to glucagon, a hormone that helps control blood sugar. It may help researchers understand a condition called 'glucagon resistance' and find better treatments.
AarhusAges 30–70 - NCT07248371Recruiting
Validating multi-omics for metabolic syndrome diseases
This study is testing a new way to look at health information (multi-omics) to better understand conditions related to metabolic syndrome, like diabetes or heart disease. It may help doctors find more personalized treatments.
TaoyuanAges 20 years+ - NCT07237750Recruiting
Weight loss trial: endoscopy procedure vs lifestyle changes
This study compares a new endoscopic procedure (a stomach tightening treatment done through a tube in your mouth) with a structured diet and exercise program to help with weight loss. It is for Asian adults who have tried and failed to lose weight before.
Beijing, Beijing MunicipalityAges 18–65 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT07185932RecruitingEarly Phase 1
Rifaximin for fatty liver with metabolic issues
This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07051863Recruiting
Non-alcoholic fatty liver disease study with biobank
This study collects health information and samples from people with non-alcoholic fatty liver disease to better understand the condition. It may help researchers find new ways to diagnose or treat this liver problem.
Lugano, Canton TicinoAges 18 years+ - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT06895018Enrolling by invitation
Grape Drink Trial for Diabetes and Fatty Liver
This study tests a drink made from grape pomace (a natural byproduct) that is rich in polyphenols—compounds that may help the liver and heart. Participants have type 2 diabetes and mild fatty liver, and researchers want to see if the drink improves liver health, blood sugar, and gut bacteria over several months.
NaplesAges 35–70
Hear when a new Fatty Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fatty liver?
- Yes. Clin2 currently lists 166 recruiting fatty liver studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fatty liver trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fatty liver trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.